Get the Stockscreener App
9.71
0.41%
-0.04
After Hours:
9.71
Meiragtx Holdings Plc stock is traded at $9.71, with a volume of 499.91K.
It is down -0.41% in the last 24 hours and up +3.30% over the past month.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.
See More
Previous Close:
$9.75
Open:
$9.8
24h Volume:
499.91K
Relative Volume:
0.63
Market Cap:
$899.24M
Revenue:
$79.76M
Net Income/Loss:
$-120.53M
P/E Ratio:
-6.5212
EPS:
-1.489
Net Cash Flow:
$3.75M
1W Performance:
+5.43%
1M Performance:
+3.30%
6M Performance:
+12.91%
1Y Performance:
+46.68%
1-Day Range:
$9.51
$9.94
1-Week Range:
$8.90
$9.96
52-Week Range:
$6.07
$11.85
Meiragtx Holdings Plc Stock (MGTX) Company Profile
Name
Meiragtx Holdings Plc
Sector
Industry
Phone
646-860-7985
Address
655 THIRD AVENUE, NEW YORK, NY
Compare MGTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MGTX
Meiragtx Holdings Plc
|
9.71 | 902.94M | 79.76M | -120.53M | 3.75M | -1.489 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Meiragtx Holdings Plc Stock (MGTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | H.C. Wainwright | Buy |
| Oct-21-25 | Initiated | Raymond James | Strong Buy |
| Jul-31-24 | Resumed | Chardan Capital Markets | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Sep-15-20 | Resumed | BofA Securities | Buy |
| Sep-03-19 | Initiated | Piper Jaffray | Overweight |
| Feb-27-19 | Reiterated | Chardan Capital Markets | Buy |
| Jul-03-18 | Initiated | Barclays | Overweight |
| Jul-03-18 | Initiated | BofA/Merrill | Buy |
View All
Meiragtx Holdings Plc Stock (MGTX) Latest News
What Could MeiraGTx’s Latest Equity Award Reveal About Long-Term Alignment? - Kalkine Media
MeiraGTx Holdings plc Announces 2026 Annual Meeting Results and Auditor Appointment - Minichart
MeiraGTx (MGTX) director Harris Keith R. granted 106,441 restricted share units - Stock Titan
Director at MeiraGTx (NASDAQ: MGTX) receives 60,000 RSUs grant - Stock Titan
MeiraGTx shareholders elect directors and approve auditor at annual meeting - Investing.com
MeiraGTx Shareholders Back Board Slate and Auditor Renewal - TipRanks
MeiraGTx (MGTX) investors back board slate and Ernst & Young - Stock Titan
MeiraGTx (MGTX) awards 60,000 RSUs tied to Perceptive Advisors board service - Stock Titan
MeiraGTx Holdings PLC (MGTX) reports Q1 loss, lags revenue estimates - MSN
MeiraGTx (MGTX) director converts 75,000 RSUs, boosting holdings to 200,000 shares - Stock Titan
Liquidity Mapping Around (MGTX) Price Events - Stock Traders Daily
MeiraGTx Holdings stock (US58550P1012): FDA breakthrough designation lifts focus on radiation dry mo - AD HOC NEWS
MeiraGTx Holdings plc (MGTX) Presents at Jefferies Global Healthcare Conference 2026Slideshow - Seeking Alpha
MeiraGTx Q1 2026 Earnings: Wider‑than‑expected loss highlights ongoing R&D investmentEstimate Revision Count - newsline.com
MGTX: Pivotal gene therapy programs advance toward approval, with strong data and market readiness - TradingView
MeiraGTx Holdings Hits Day Low of $9.78 Amid Price Pressure - MarketsMojo
MeiraGTx Holdings plc Q1 2026 Earnings: Wider-Than-Expected Loss Highlights Clinical-Stage R&D CostsProfit Cycle Analysis - newsline.com
MeiraGTx Holdings Plc Announces Amendment To $100,000,000 Fluctuating Rate Senior Secured Loan Notes Maturity Date - marketscreener.com
Certain Stock Options of MeiraGTx Holdings plc are subject to a Lock-Up Agreement Ending on 1-JUN-2026. - marketscreener.com
Certain Restricted Stock Units of MeiraGTx Holdings plc are subject to a Lock-Up Agreement Ending on 1-JUN-2026. - marketscreener.com
Certain Ordinary Shares of MeiraGTx Holdings plc are subject to a Lock-Up Agreement Ending on 1-JUN-2026. - marketscreener.com
Why (MGTX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
MeiraGTx Holdings (MGTX) Surges 6.5% as Biotech Sector Momentum BuildsStock Analysis - thelegaladvocate.com
MeiraGTx Q1 2026 Earnings: Wider-than-Expected Loss but Stock Gains on Pipeline ProgressQuarterly Financial Update - The Legal Advocate
MeiraGTx (MGTX) CFO & COO Giroux reports bona fide gift of 7,000 shares - Stock Titan
MeiraGTx Holdings (MGTX) Edges Higher, Hovers Above Key SupportSafe Entry Stocks - The Legal Advocate
MeiraGTx Holdings (MGTX) Pulls Back Nearly 3% as Stock Tests Near Key Support LevelRisk Reversal - newsline.com
MeiraGTx Holdings | 4: Statement of changes in beneficial ownership of securities-Officer Wollin Robert J - Moomoo
MeiraGTx Holdings plc (MGTX) Q1 2026 Earnings: Wider-than-Expected Loss Stings InvestorsEarnings Call Highlights - The Legal Advocate
MeiraGTx Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineDividend Increase Stocks - newsline.com
MGTX Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances PipelinePost-Earnings Reaction - The Legal Advocate
MeiraGTx Holdings plc (MGTX) Q1 2026 Earnings: Wider-than-Expected Loss Amid Clinical ProgressEarnings Forecast Report - The Legal Advocate
MeiraGTx Q1 2026 Earnings: Wider-than-Expected Loss Highlights Cash Burn Amid Clinical ProgressEarnings Per Share - The Legal Advocate
Chardan Capital Maintains MeiraGTx Holdings (MGTX) Buy Recommendation - MSN
MeiraGTx Holdings stock (US58550P1012): Insider selling draws attention as gene therapy story evolve - AD HOC NEWS
Can MeiraGTx Holdings PLC (MGTX) Stock Double? Cash Runway Offers a Hint - Insider Monkey
Meiragtx president & CEO Forbes Alexandria sells $568,540 in shares By Investing.com - Investing.com India
Insider Sell Alert: Alexandria Forbes Sells 62,000 Shares of Mei - GuruFocus
Meiragtx president & CEO Forbes Alexandria sells $568,540 in shares - Investing.com UK
MeiraGTx (MGTX) CEO sells 62,000 shares under Rule 10b5-1 plan - Stock Titan
MGTX (NASDAQ) affiliate lists 62,000-share sale in Form 144 filing - Stock Titan
10 Best Gene Therapy Stocks to Buy in 2026 - Insider Monkey
MeiraGTx Holdings stock (US58550P1012): gene therapy player in focus after recent earnings and partn - AD HOC NEWS
MeiraGTx Holdings plc (NASDAQ:MGTX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year - Sahm
Understanding Momentum Shifts in (MGTX) - Stock Traders Daily
Here's What Analysts Are Forecasting For MeiraGTx Holdings plc (NASDAQ:MGTX) After Its First-Quarter Results - Yahoo Finance
MeiraGTx Falls 5.5% as MGTX Shares Slip, Investors Keep Watch Next Week - TechStock²
Will MeiraGTx Holdings PLC (MGTX) report negative Q1 earnings? What you should know - MSN
MGTX Maintained by RBC Capital -- Price Target Raised to $25.00 - GuruFocus
MeiraGTx (NASDAQ:MGTX) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says - MarketBeat
RBC Capital Maintains MeiraGTx Holdings(MGTX.US) With Buy Rating, Raises Target Price to $25 - Moomoo
Meiragtx Holdings Plc Stock (MGTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):